The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
Hypothermia for Cardiac Arrest in Paediatrics
Scientific title
Hypothermia for Cardiac Arrest in Paediatrics (HypCAP) - Pilot Study
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cardiac Arrest 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Coronary heart disease
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Study type
Description of intervention(s) / exposure
Other interventions - Normothermia
Other interventions - Hypothermia

Active Comparator: 1 -

Experimental: 2 -

Other interventions: Normothermia
Patients randomized to the Normothermia arm (esophageal temp 36.5-37.5 ºC) will be maintained at an esophageal temperature of 36.5-37.5ºC for 48 hours. Patients who are hypothermic (temperature < 35 ºC) when randomized to the normothermia group will be rewarmed slowly using the servo-controlled mattress. Patients who are hyperthermic following randomization to the normothermia group will be actively cooled to normothermia using the servo-controlled mattress. Neuromuscular blockers will be administered as needed intravenously in both groups of patients to prevent shivering.

Other interventions: Hypothermia
Patients randomized to the Hypothermia arm (esophageal temp 33º to 34 °C) will be cooled rapidly using the cooling protocol developed for the Hypothermia Paediatric Head Injury Trial. A temperature probe will be placed in the esophagus and its position confirmed using a chest radiograph. Patients will be placed on a servo-controlled cooling blanket and covered in crushed ice (in sealed plastic bags covered by pillow cases) and a second cooling blanket. Once the esophageal temperature reaches 34.0ºC, the ice and second cooling blanket will be removed and esophageal temperature will be maintained at 33º to 34 °C for 48 hours using the servo-controlled cooling mattress. Patients treated with ECMO will be cooled using the extracorporeal circuit cooling-device. Rewarming will be done at a rate of 0.5 ºC every 2 hours until an esophageal temperature of 36.5 ºC is reached. Thereafter temperature will be recorded but not controlled by surface cooling.

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Primary outcome [1] 0 0
The percentage of children achieving a "good outcome", that is, a PCPC of 1-3 will be assessed using the Paediatric Cerebral Performance Category scores
Timepoint [1] 0 0
Assessed at 12 months post cardiac arrest
Secondary outcome [1] 0 0
Cognitive and motor measures
Timepoint [1] 0 0
Assessed at 12 months post-arrest
Secondary outcome [2] 0 0
Timepoint [2] 0 0
Assessed at 1, 3, 6, and 12 months post-arrest
Secondary outcome [3] 0 0
Cerebral edema
Timepoint [3] 0 0
12 months
Secondary outcome [4] 0 0
Adverse effects of hypothermia therapy
Timepoint [4] 0 0
12 months

Key inclusion criteria
- Informed consent by parent or legal guardian

- Age = 38 weeks gestation up to and including 17 years

- Patient admitted with a diagnosis of a cardiac arrest requiring compressions =3

- Remain comatose i.e. have Glasgow Coma Score less than or equal to 10 assessed at the
tertiary level pediatric hospital at least 1 hour post- cardiac arrest

- Invasive mechanical ventilation
Minimum age
No limit
Maximum age
17 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
- Cardiac arrest lasting =45 minutes, irregardless of commencement of ECMO

- Refractory hemorrhagic shock

- Dysrhythmia leading to cardiac arrest, where cooling would be part of standard therapy

- Suspected diagnosis of brain death as defined as fixed and dilated pupils, Glasgow
Coma Score of 3 and no evidence of brain function on neurological examination

- Patients who have had a prolonged cardiac arrest at the scene of a trauma

- Decision to withhold (DNR) or withdraw life sustaining therapies

- Acute Birth asphyxia

- Terminal illness, not expected to survive 12 months

- Cardiac arrest caused by septic shock

- Severe neurodevelopmental disability or persistent vegetative state prior to cardiac

- Near drowning in ice water and temperature <32ºC on admission to study site

- It has been more than 6 hours following cardiac arrest (estimated by first responder)

- Previous enrolment in the HypCAP Pilot Study

- Pregnant

- Parent/Guardian refuse consent

- Responsible physician refuses to enrol patient

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?

The people assessing the outcomes
Intervention assignment
Other design features
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
State/province [1] 0 0
Country [2] 0 0
State/province [2] 0 0
Country [3] 0 0
New Zealand
State/province [3] 0 0
Country [4] 0 0
United Kingdom
State/province [4] 0 0

Funding & Sponsors
Primary sponsor type
The Hospital for Sick Children

Ethics approval
Ethics application status

Brief summary
The investigators hypothesize that, following cardiac arrest in pediatric patients,
hypothermia therapy will improve the proportion of patients with a good functional outcome
compared to a normothermic control group.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Jamie Hutchison, MD
Address 0 0
The Hospital for Sick Children
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No data has been provided for results reporting
Summary results
Other publications